연구성과로 돌아가기

2020 연구자 정보 (41 / 997)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Hanash, Samir M.
(Hanash, SM) ⓘ 		Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA ⓘ
ⓘ
ⓘ 		[JCR상위 2.7] Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer ⓘ SCIE ⓘ 2.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ glopez@mdanderson.org;gcalin@mdanderson.org; ⓘ
He, William Ruixian
(He, WR) ⓘ 		Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA ⓘ
ⓘ
ⓘ 		[JCR상위 2.7] Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer ⓘ SCIE ⓘ 2.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ glopez@mdanderson.org;gcalin@mdanderson.org; ⓘ
Ho, G. F.
(Ho, GF) ⓘ 		Univ Malaya, Med Ctr, Clin Oncol Unit, Kuala Lumpur, Malaysia ⓘ B-8634-2010
HO, GWO FUANG ⓘ 		0000-0002-2620-9174
Ho, Gwo Fuang ⓘ 		[JCR상위 2.7] Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study ⓘ SCIE ⓘ 2.7 ONCOLOGY ⓘ ⓘ
Hong, S-B.
(Hong, SB) ⓘ 		ISU Abxis Co Ltd, Drug Dev, Seongnam, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 2.7] Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) ⓘ SCIE ⓘ 2.7 ONCOLOGY ⓘ ⓘ
Huang, Guoliang
(Huang, GL) ⓘ 		Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
Guangdong Med Univ, Dongguan Sci Res Ctr, China Amer Canc Res Inst, Dongguan, Peoples R China ⓘ 		H-1625-2011
Huang, Guoliang ⓘ 		0000-0002-8902-8100
Huang, Guoliang ⓘ 		[JCR상위 2.7] Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer ⓘ SCIE ⓘ 2.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ glopez@mdanderson.org;gcalin@mdanderson.org; ⓘ
Huang, J.
(Huang, J) ⓘ 		Merck Pte Ltd, Oncol, Singapore, Singapore ⓘ
ⓘ
ⓘ 		[JCR상위 2.7] Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study ⓘ SCIE ⓘ 2.7 ONCOLOGY ⓘ ⓘ
Huang, Li
(Huang, L) ⓘ 		Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA ⓘ MAH-9678-2025
Huang, Lihaoyun ⓘ
ⓘ 		[JCR상위 2.7] Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer ⓘ SCIE ⓘ 2.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ glopez@mdanderson.org;gcalin@mdanderson.org; ⓘ
Ivan, Cristina
(Ivan, C) ⓘ 		Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Houston, TX 77030 USA ⓘ
ⓘ 		0000-0002-4848-0168
Ivan, Cristina ⓘ 		[JCR상위 2.7] Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer ⓘ SCIE ⓘ 2.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ glopez@mdanderson.org;gcalin@mdanderson.org; ⓘ
Kapitanovic, Sanja
(Kapitanovic, S) ⓘ 		Rudjer Boskovic Inst, Div Mol Med, Zagreb, Croatia ⓘ
ⓘ 		0000-0001-8788-3085
Kapitanovic, Sanja ⓘ 		[JCR상위 2.7] Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer ⓘ SCIE ⓘ 2.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ glopez@mdanderson.org;gcalin@mdanderson.org; ⓘ
Katayama, Hiroyuki
(Katayama, H) ⓘ 		Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA ⓘ
ⓘ
ⓘ 		[JCR상위 2.7] Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer ⓘ SCIE ⓘ 2.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ glopez@mdanderson.org;gcalin@mdanderson.org; ⓘ
Keam, B.
(Keam, B) ⓘ 		Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 2.7] Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) ⓘ SCIE ⓘ 2.7 ONCOLOGY ⓘ ⓘ
Kim, S-B.
(Kim, SB) ⓘ 		제1저자 Asan Med Ctr, Dept Oncol, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 2.7] Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) ⓘ SCIE ⓘ 2.7 ONCOLOGY ⓘ ⓘ
Kim, Sung-Hyun
(Kim, SH) ⓘ 		Korea Polytech Coll, Dept Biomed Anal, Chungnam, South Korea
Kyungpook Natl Univ, Sch Anim BT Sci, Dept Anim Sci & Biotechnol, Sangju, South Korea
Kongju Natl Univ, Dept Compan & Lab Anim Sci, Yesan 32439, South Korea
Dong A Univ Med Ctr, Busan, South Korea
Dong A Med Ctr, Busan, South Korea
Dong A Univ, Dept Internal Med, Dong A Med Ctr, Coll Med, Busan, South Korea ⓘ 		E-8074-2011
Hyun-Jung, Kim ⓘ
ⓘ 		[JCR상위 2.7] 6-Shogaol, an active ingredient of ginger, inhibits osteoclastogenesis and alveolar bone resorption in ligature-induced periodontitis in mice
[JCR상위 78.1] Effects of Dimethyl Sulfoxide on the Pluripotency and Differentiation Capacity of Mouse Embryonic Stem Cells
[JCR상위 27.0] Targeting X chromosome-linked inhibitor of apoptosis protein in mucoepidermoid carcinoma of the head and neck: A novel therapeutic strategy using nitidine chloride
[JCR상위 79.6] Effect of Stem Cell Source and Dose on Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Idiopathic Aplastic Anemia: Data from the Korean Aplastic Anemia Trials
[JCR상위 50.7] Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis
[JCR상위 45.4] The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study) ⓘ 		SCIE ⓘ 2.7 DENTISTRY, ORAL SURGERY & MEDICINE
BIOTECHNOLOGY & APPLIED MICROBIOLOGY;CELL & TISSUE ENGINEERING;GENETICS & HEREDITY
GENETICS & HEREDITY;MEDICINE, RESEARCH & EXPERIMENTAL
HEMATOLOGY
HEMATOLOGY;ONCOLOGY ⓘ 		ylec@knu.ac.kr;ylee@knu.ac.kr;
ok4325@knu.ac.kr;
sky21sm@snu.ac.kr;efiwdsc@snu.ac.kr;
kimhawkmd@gmail.com;
drjejung@chonnam.ac.kr;HEMAKIM@yuhs.ac;
ckmin@catholic.ac.kr; ⓘ
Kim, T. M.
(Kim, TM) ⓘ 		Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 2.7] Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) ⓘ SCIE ⓘ 2.7 ONCOLOGY ⓘ ⓘ
Kim, T. W.
(Kim, TW) ⓘ 		Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea ⓘ GRX-7323-2022
Kim, Tae Won ⓘ
ⓘ 		[JCR상위 2.7] Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study ⓘ SCIE ⓘ 2.7 ONCOLOGY ⓘ ⓘ
페이지 이동: